In a report published by Piper Jaffray, analyst Kevin K. Ellich maintained his Neutral rating and lowered the price target on Amedisys AMED from $12 to $10.
Piper Jaffray reported that, “Revenues decreased 2.0% y/y to $362.9 MM, which was lower than our estimate and consensus of $373 MM. Adjusted EBITDA decreased 35.1% y/ y to $23.3 MM, which was roughly in-line with our estimate of $22.9 MM, while EBITDA margin declined 326 bps y/y and 23 bps sequentially to 6.41%, which was 27 bps higher than our projection of 6.15%. Adjusted EPS of $0.23 was $0.02 higher than our estimate of $0.21 and a penny higher than consensus of $0.22. The change in AMED's contract with Humana had a negative $0.06 impact. Operating cash flow was $12.6 MM in the quarter, while DSO was 41 days, which is up from 35 days in 4Q11. The uptick in DSO was primarily attributable to converting Hospice centers to the company's point-of-care technology which slowed billings. Hospice avg. length of stay increased to 105 days from 93 in 4Q11.”
Shares of Amedisys closed at $11.07 on Tuesday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in